Back to Search
MOHANAMBAL GOUNDER, MD
MD
Internal Medicine Physician
NPI: 1548316664Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
14544101(NY)
Research & Publications (12)
Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.
PMID 19038763·Lancet Oncol·2008
6-review
Optimal modeling for phase I design of a two drug combination-results of a phase I study of cisplatin with 9-nitrocamptothecin.
PMID 18600301·Invest New Drugs·2008
3-trial
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
PMID 18454051·Anticancer Drugs·2008
3-trial
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
PMID 17943230·Invest New Drugs·2008
4-observational
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
PMID 17908982·Clin Cancer Res·2007
3-trial
G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis.
PMID 17459049·Br J Haematol·2007
8-other
A study of the interactions between carboplatin and blood plasma proteins using size exclusion chromatography coupled to inductively coupled plasma mass spectrometry.
PMID 17340090·Anal Bioanal Chem·2007
8-other
Development of a bioanalytical liquid chromatography method for quantitation of 9-nitrocamptothecin in human plasma.
PMID 14659436·J Chromatogr B Analyt Technol Biomed Life Sci·2004
7-preclinical
A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.
PMID 12942041·Med Sci Monit·2003
3-trial
Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin.
PMID 12810652·Cancer Res·2003
7-preclinical
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
PMID 12738720·Clin Cancer Res·2003
3-trial
Transcription-dependent degradation of topoisomerase I-DNA covalent complexes.
PMID 12640119·Mol Cell Biol·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1 MAIN ST
ROOSEVELT ISLAND, NY 10044 - Phone
- (914) 381-8900
Quick Facts
- NPI
- 1548316664
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 12
Are you this provider?
Claim Your Profile